Jamjoom Pharma profit rises 22% to SAR 103M in Q1 2024

Jamjoom Pharma profit rises 22% to SAR 103M in Q1 2024

09/05/2024 Argaam Exclusive

View other reports

Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) posted a net profit of SAR 103 million in Q1 2024, a 22% increase from SAR 84.4 million a year earlier.



Current Quarter Comparison (M)

Compared With The
Item Q1 2023 Q1 2024 Change‬
Revenues 300.85 385.46 28.1 %
Gross Income 199.61 249.40 24.9 %
Operating Income 93.91 126.58 34.8 %
Net Income 84.40 102.97 22.0 %
Average Shares 70.00 70.00 -
EPS (Riyals) 1.21 1.47 22.0 %

The positive performance was driven by the increase in sales, which were slightly offset by the devaluation impact from the Egyptian pound.

 

Sequentially, net profit jumped 131.5% from SAR 44.48 million in Q4 2023 on higher sales, improvement in gross margin, in addition to better absorption of operating expenses.

 

Shareholders’ equity, no minority interest, stood at SAR 1.46 billion as of March 31, 2024, compared to SAR 1.26 billion a year earlier.

 

Attached Documents

 



Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
Q1 2015 - - - - - -
Q2 2015 - - - - - -
Q3 2015 - - - - - -
Q4 2015 - - - - - -
Q1 2016 - - - - - -
Q2 2016 - - - - - -
Q3 2016 - - - - - -
Q4 2016 - - - - - -
Q1 2017 - - - - - -
Q2 2017 - - - - - -
Q3 2017 - - - - - -
Q4 2017 - - - - - -
Q1 2018 - - - - - -
Q2 2018 - - - - - -
Q3 2018 - - - - - -
Q4 2018 - - - - - -
Q1 2019 - - - - - -
Q2 2019 - - - - - -
Q3 2019 - - - - - -
Q4 2019 - - - - - -
Q1 2020 - - - - - -
Q2 2020 - - - - - -
Q3 2020 - - - - - -
Q4 2020 - - - - - -
Q1 2021 121.82 - 77.37 - 14.74 -
Q2 2021 193.05 - 124.75 - 49.73 -
Q3 2021 - - - - - -
Q4 2021 - - - - - -
Q1 2022 243.78 100.1 % 164.32 112.4 % 77.42 425.2 %
Q2 2022 238.30 23.4 % 153.06 22.7 % 57.61 15.9 %
Q3 2022 237.76 - 151.13 - 60.03 -
Q4 2022 196.84 - 125.41 - 38.26 -
Q1 2023 300.85 23.4 % 199.61 21.5 % 93.91 21.3 %
Q2 2023 298.40 25.2 % 198.10 29.4 % 92.56 60.7 %
Q3 2023 292.61 23.1 % 187.23 23.9 % 84.67 41.1 %
Q4 2023 207.86 5.6 % 118.86 (5.2 %) 42.24 10.4 %
Q1 2024 385.46 28.1 % 249.40 24.9 % 126.58 34.8 %


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items EPS Before XO Items
Q1 2015 - - - - - -
Q2 2015 - - - - - -
Q3 2015 - - - - - -
Q4 2015 - - - - - -
Q1 2016 - - - - - -
Q2 2016 - - - - - -
Q3 2016 - - - - - -
Q4 2016 - - - - - -
Q1 2017 - - - - - -
Q2 2017 - - - - - -
Q3 2017 - - - - - -
Q4 2017 - - - - - -
Q1 2018 - - - - - -
Q2 2018 - - - - - -
Q3 2018 - - - - - -
Q4 2018 - - - - - -
Q1 2019 - - - - - -
Q2 2019 - - - - - -
Q3 2019 - - - - - -
Q4 2019 - - - - - -
Q1 2020 - - - - - -
Q2 2020 - - - - - -
Q3 2020 - - - - - -
Q4 2020 - - - - - -
Q1 2021 10.98 - 0.16 - 10.98 0.16
Q2 2021 41.19 - 0.59 - 41.19 0.59
Q3 2021 - - - - - -
Q4 2021 - - - - - -
Q1 2022 43.53 296.3 % 0.62 (28.75) 72.28 1.03
Q2 2022 50.42 22.4 % 0.72 (4.27) 54.69 0.78
Q3 2022 45.60 - 0.65 (7.96) 53.56 0.77
Q4 2022 31.76 - 0.45 (6.98) 38.73 0.55
Q1 2023 84.40 93.9 % 1.21 - 84.40 1.21
Q2 2023 86.27 71.1 % 1.23 - 86.27 1.23
Q3 2023 77.25 69.4 % 1.10 - 77.25 1.10
Q4 2023 44.48 40.1 % 0.64 - 44.48 0.64
Q1 2024 102.97 22.0 % 1.47 - 102.97 1.47

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 64.79 % 28.15 % 23.92 %
Q1 2023 64.62 % 28.21 % 23.76 %
Q2 2023 65.22 % 29.98 % 25.44 %
Q3 2023 65.25 % 30.78 % 26.33 %
Q4 2023 64.00 % 30.92 % 26.59 %
Q1 2024 63.63 % 31.58 % 26.26 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2015 - - - -
Q2 2015 - - - -
Q3 2015 - - - -
Q4 2015 - - - -
Q1 2016 - - - -
Q2 2016 - - - -
Q3 2016 - - - -
Q4 2016 - - - -
Q1 2017 - - - -
Q2 2017 - - - -
Q3 2017 - - - -
Q4 2017 - - - -
Q1 2018 - - - -
Q2 2018 - - - -
Q3 2018 - - - -
Q4 2018 - - - -
Q1 2019 - - - -
Q2 2019 - - - -
Q3 2019 - - - -
Q4 2019 - - - -
Q1 2020 - - - -
Q2 2020 - - - -
Q3 2020 - - - -
Q4 2020 - - - -
Q1 2021 70.00 - - -
Q2 2021 70.00 - - 16.98
Q3 2021 - - - -
Q4 2021 - - - -
Q1 2022 70.00 - - 17.67
Q2 2022 70.00 - - 18.03
Q3 2022 70.00 - - 18.34
Q4 2022 70.00 2.45 3.13 17.38
Q1 2023 70.00 3.03 3.31 18.13
Q2 2023 70.00 3.54 3.76 19.36
Q3 2023 70.00 4.00 4.09 19.45
Q4 2023 70.00 4.18 4.18 20.06
Q1 2024 70.00 4.44 4.44 20.88

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 - - -
Q1 2023 - - -
Q2 2023 25.26 23.82 4.62
Q3 2023 28.98 28.28 5.95
Q4 2023 27.53 27.53 5.73
Q1 2024 28.59 28.59 6.08

Business Segments (Million)

Compared With The
Period Pharmaceutical products Consumer Health Products
Q1 2021 107.12 14.70
Q2 2021 174.82 18.23
Q1 2022 203.09 40.70
Q2 2022 207.60 30.70
Q3 2022 206.65 31.11
Q4 2022 180.05 16.79
Q1 2023 258.50 42.35
Q2 2023 256.14 42.26
Q3 2023 251.49 41.12
Q4 2023 189.49 18.36
Q1 2024 334.33 51.13

Analysts Estimates (Million)

Item Q1 2024 (e) Q1 2024 (a) Change‬
Average 89.29 102.97 15.32 %

Estimates vs Actual (Million)

Item Q1 2024 (e) Q1 2024 (a) Change
OSOOL AND BAKHEET 102.15 102.97 0.8 %
GIB Capital 102.00 102.97 1.0 %
Al Rajhi Capital 99.00 102.97 4.0 %
United Securities Company 54.00 102.97 90.7 %

Current
Market Cap (M Riyal) 10,990.00
Enterprise Value (EV) (M) 10,868.18
Shares Outstanding ((M)) 70.00
EPS ( Riyal) (TTM) 4.99
Book Value (BV) ( Riyal) 20.64
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 31.45
P/E (TTM) 31.45
Price/book 7.61
Return on Average Assets (%) (TTM) 19.9
Return on Average Equity (%) (TTM) 24.9

Share Price

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)


Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.